Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606.

A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders.

A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.

United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement.

Liquidia's lead drug Yutrepia has gained significant market traction with over 5,000 patients started on therapy as of July 2026, but the stock has underperformed due to heavy reliance on a single product, ongoing patent litigation with United Therapeutics, competitive pressures, and rising R&D costs. Analysts recommend avoiding the stock due to an unfavorable risk-reward profile.

Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.

Liquidia Corporation (LQDA) is drawing attention from options traders due to high implied volatility in its Jan 15, 2027 $22.50 Call options, suggesting investors expect a significant price movement. The company holds a Zacks Rank #3 (Hold) rating in the Medical - Biomedical and Genetics industry, with analyst consensus estimates for the current quarter recently improving from 74 cents to 82 cents per share. Options traders may be positioning to sell premium and capture decay, betting the stock won't move as dramatically as the implied volatility suggests.

Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.

Liquidia's stock fell 20% week-to-date following its Q2 earnings report, despite beating revenue expectations ($171.7M vs. $171M consensus) and posting a $74.7M net profit. The decline was attributed to the stock's steep 155% year-to-date run-up creating unrealistic expectations. The company's pulmonary hypertension drug Yutrepia is performing well, though concerns remain about its reliance on a single molecule.

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

Liquidia Corporation's Board Chairman Stephen Bloch sold 70,234 shares worth $2.53 million in March 2026. However, the article suggests this is not a red flag for investors, as Bloch retained over 2 million shares and the sale represents only 3.02% of his holdings. The transaction appears to reflect liquidity management rather than loss of confidence. Liquidia's stock has surged 159.5% over the past year, with the company achieving strong financial performance including $158.3 million in 2025 revenue and consecutive profitable quarters.

Liquidia's Chief Commercial Officer Scott Moomaw sold 80,000 shares worth approximately $2.8 million on March 9, 2026, representing 29.74% of his direct holdings. The sale was executed through a pre-arranged trading plan and appears to be routine liquidity management rather than a loss of confidence. Moomaw retained 188,954 shares and 25,300 stock options, maintaining significant alignment with shareholders. The transaction occurred as Liquidia's flagship product Yutrepia generated $90.1 million in Q4 2025 sales, and the company achieved its first operating profit of $19.8 million in the same quarter.